A new insight into hepatitis C vaccine development (Q21296858)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20625493%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

review article

3 references

20 July 2020

25 October 2022

A new insight into hepatitis C vaccine development (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20625493%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

0 references

1 reference

20 July 2020

viral hepatitis vaccines

1 reference

1

Chun I Yu

Chun I

Yu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20625493%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

2

Bor-Luen Chiang

Bor-Luen

Chiang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20625493%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

English

0 references

publication date

13 June 2010

7 references

23 March 2019

21 March 2019

20 June 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20625493%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 July 2020

20 July 2020

25 October 2022

Journal of Biomedicine and Biotechnology

7 references

23 March 2019

21 March 2019

20 June 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20625493%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 July 2020

20 July 2020

25 October 2022

2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20625493%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

548280

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20625493%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 3.0 Unported

7 February 2020

copyright license

start time

1 January 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Human occludin is a hepatitis C virus entry factor required for infection of mouse cells

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27–restricted human immune response

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Stable Cytotoxic T Cell Escape Mutation in Hepatitis C Virus Is Linked to Maintenance of Viral Fitness

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and [...]

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Identification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 Protein

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Isolation and Characterization of Broadly Neutralizing Human Monoclonal Antibodies to the E1 Glycoprotein of Hepatitis C Virus

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Cellular immune selection with hepatitis C virus persistence in humans

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Immune evasion versus recovery after acute hepatitis C virus infection from a shared source

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

The CCR5- 32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

CD8 Epitope Escape and Reversion in Acute HCV Infection

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Global epidemiology of hepatitis C virus infection

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Complete replication of hepatitis C virus in cell culture

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Analysis of a successful immune response against hepatitis C virus

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection

10 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Cellular and molecular biology of HCV infection and hepatitis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Evolutionary struggles between NK cells and viruses

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Dendritic cells prime natural killer cells by trans-presenting interleukin 15

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Treating viral hepatitis C: efficacy, side effects, and complications

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Neutralizing antibody response during acute and chronic hepatitis C virus infection

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Hepatitis C virus infection in the United States

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

IRF3 mediates a TLR3/TLR4-specific antiviral gene program

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

Clinical outcomes after transfusion-associated hepatitis C.

30 May 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Dendritic cells support the in vivo development and maintenance of NK cells via IL-15 trans-presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Cationic microparticles are a potent delivery system for a HCV DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F548280

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896694

HLA class II favors clearance of HCV infection and progression of the chronic liver damage

29 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20625493

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1155/2010/548280

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20625493%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20625493%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference